Introduction {#s1}
============

Hyperkalemia is a medical emergency which may lead to sudden cardiac death secondary to cardiac arrhythmias if left untreated. Any patient with history and physical examination which raise clinical suspicion of hyperkalemia requires an immediate 12-lead electrocardiogram (ECG) to ascertain whether ECG manifestations of hyperkalemia are present or not. Hyperkalemia is considered to be severe when the serum potassium level is 7.0 mEq/L or greater. The mortality among patients with severe hyperkalemia can be as high as 67% if not corrected in a timely manner \[[@R01], [@R02]\].

Case Report {#s2}
===========

A 52-year-old man presented to the emergency room with complaints of weakness and lethargy. According to the patient, the symptoms started after he skipped a scheduled hemodialysis session for unknown reason. His medical history included end-stage renal disease requiring hemodialysis three times/week, diabetes mellitus type 2, hypertension, congestive heart failure, chronic obstructive pulmonary disease, acquired immunodeficiency syndrome (AIDS) and chronic hepatitis C. He is an active smoker and enrolled in methadone maintenance program in view of prior intravenous drug use. His home medications included aspirin, atorvastatin, lisinopril, hydralazine, metoprolol, isosorbide mononitrate, insulin, albuterol, fluticasone/salmeterol and tiotropium. On arrival to the emergency room, his vitals were heart rate of 118 beats/min regular rhythm, blood pressure of 110/50 mm Hg, respiratory rate of 16 breaths/min and an oxygen saturation of 87% while breathing on 2 L/min of nasal oxygen. The cardiopulmonary examination showed bilateral air entry without any adventitious sounds and normal heart sounds without murmurs, gallop or rub. The abdomen was soft with no organomegaly and normal bowel sounds. Extremities were warm and well perfused without edema, cyanosis, or clubbing. Neurologic examination was unremarkable. A 12-lead ECG ([Fig. 1](#F1){ref-type="fig"}) showed the hallmark features of hyperkalemia including left bundle branch block, hyper-acute T waves, sinus tachycardia at 118 beats/min and wide QRS complex. The initial laboratory investigations showed serum sodium of 123 mEq/L, potassium of 8.8 mEq/L, blood urea nitrogen of 133 mg/dL, creatinine of 10.6 mg/dL, pH 6.9, pCO~2~ of 56 mm Hg, pO~2~ of 75 mm Hg and HCO~3~^-^ of 10.7 mmol/L. He was given a cocktail of intravenous calcium gluconate, insulin, dextrose, and bicarbonate for severe hyperkalemia; however, his repeat serum potassium level remained elevated for which he underwent emergent hemodialysis. A repeat ECG ([Fig. 2](#F2){ref-type="fig"}) after hemodialysis showed a resolution of the left bundle branch pattern along with normal rhythm and axis, left ventricular hypertrophy with strain pattern and persistent prolonged QT interval. A repeat serum chemistry after hemodialysis showed improvement in serum potassium level to 4.3 mEq/L. The persistent prolongation of the QT interval was attributed to chronic use of methadone.

![Electrocardiogram showed left bundle branch pattern, along with tall T waves and wide QRS complex.](cr-08-077-g001){#F1}

![Electrocardiogram after the correction of hyperkalemia.](cr-08-077-g002){#F2}

Discussion {#s3}
==========

Hyperkalemia is one of the most common causes of the cardiac arrhythmias seen in clinical practice. It is important to note that the relationship between potassium levels and ECG findings varies between patients and many less known and less recognized ECG changes associated with hyperkalemia are reported in the literature which includes hemiblock, right bundle branch block, left bundle branch block, bifascicular block, or trifascicular block due to depressed intraventricular conduction. Although the left bundle branch block due to severe hyperkalemia has been reported previously but its exact prevalence and relation to potassium level is not known. Geriatric population in particular is vulnerable to develop severe hyperkalemia due to multiple factors, of which polypharmacy is one of the most common contributing factors. Beta-adrenergic blocker, NSAID, aldosterone antagonist, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker and digoxin are common medications known to contribute to hyperkalemia. Comorbid conditions \[[@R03], [@R04]\] like diabetes mellitus, hypertension, coronary artery disease and chronic kidney disease often further impede homeostatic function which magnifies the risk of developing hyperkalemia. The ratio of intracellular to extracellular potassium concentration is the primary determinant of cell membrane potential in most cells \[[@R05]\]. Normally, intracellular concentration is approximately 120 mEq/L, whereas extracellular potassium concentration is approximately 4 mEq/L. The contribution of potassium to resting membrane potential is related to this ratio of intracellular to extracellular potassium; thus, small changes in extracellular potassium can result in large changes in the intracellular to extracellular potassium ratio, hence result in large changes in resting membrane potential. The resting membrane potential is important in all electrically active cells, including neurons, voluntary and involuntary muscles. Total body potassium levels are regulated mostly by the kidneys, with only 5-10% of ingested potassium excreted in the feces. The renal excretion of potassium is determined by the rate of potassium filtration across the glomerular basement membrane and by the rate of its secretion and resorption in the distal tubules of the nephron. This equilibrium is regulated by insulin \[[@R06]\], catecholamines \[[@R09], [@R10]\] and to a lesser extent, by acid-base balance \[[@R11]\] and plasma tonicity.

The sequence of ECG manifestations is directly linked to severity of hyperkalemia as depicted in [Table 1](#T1){ref-type="table"} \[[@R14]\]. The earliest ECG manifestation of hyperkalemia is the appearance of narrow-based, peaked T waves. These T waves are of relatively short duration, approximately 150 - 250 ms. Peaked T waves are usually seen at potassium concentrations greater than 5.5 mEq/L and are best seen in leads II, III, and V~2~ through V~4~, but are present in only 22% of patients with hyperkalemia. Hyperkalemia also causes delayed intraventricular and atrioventricular conduction and as the intraventricular conduction delay worsens, the QRS complex may take on the appearance of a left or right bundle branch block configuration. A clue that these ECG changes are due to hyperkalemia, and not to bundle branch disease, is that, in hyperkalemia the conduction delay persists throughout the QRS complex and not just in the initial or terminal portions, as seen at left and right bundle branch block. Another rare manifestation of hyperkalemia is ST segment elevation or pseudo infarction \[[@R15]\]. For the management of hyperkalemia most authorities recommend immediate treatment when ECG changes are present or when serum potassium levels are greater than 6.5 mEq/L regardless of the ECG findings. The treatment for hyperkalemia can be divided into three distinct categories: firstly, antagonize the effects of hyperkalemia at the cellular level (membrane stabilization); secondly, decrease serum potassium levels by promoting the influx of potassium into cells throughout the body; and lastly, remove potassium from the body through kayexalate \[[@R18], [@R19]\] or hemodialysis. The effects of intravenous calcium therapy occur within 1 - 3 min and last for only 30 - 60 min \[[@R20]\]. Therefore, more definitive treatment is needed to lower serum potassium levels. Calcium gluconate is the preferred preparation of intravenous calcium. The recommended dose of 10 mL of a 10% calcium gluconate solution infused over 2 - 3 min antagonizes myocardial effects of hyperkalemia \[[@R21], [@R22]\]. If all pharmacological management fails, then the next step would be emergent dialysis. Hyperkalemia is often a reason of elimination of useful medications such as aldosterone antagonist, angiotensin-converting enzyme inhibitor, and angiotensin II receptor blocker, which has a mortality benefit in some chronic conditions like congestive heart failure and chronic kidney disease. The emergence of new potassium binders allows the continued use of medications such as renin-angiotensin aldosterone system inhibitors even in patients who are prone to develop hyperkalemia. This may result in improved outcomes in patients with cardiovascular and renal diseases. Lastly, thorough knowledge of the ECG manifestations of hyperkalemia is imperative to ensure prompt treatment of this potentially life-threatening condition.

###### Electrocardiographic Manifestations of Serum Hyperkalemia Relative to Serum Potassium Level \[[@R14]\]

  ----------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mild hyperkalemia (5.5 - 6.5 mEq/L)       Tall, tent-shaped ("peaked") T waves with narrow base, best seen in precordial leads
  Moderate hyperkalemia (6.5 - 8.0 mEq/L)   Peaked T waves, prolonged PR interval, decreased amplitude of P waves, widening of QRS complex
  Severe hyperkalemia (\> 8.0 mEq/L)        Absence of P wave, intraventricular blocks, fascicular blocks, bundle branch blocks, QRS axis shift, progressive widening of the QRS complex resulting in bizarre QRS morphology, Eventual "sine-wave" pattern (sinoventricular rhythm), VF, asystole
  ----------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
